Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | PHASE1 | COMPLETED | 32 | — | — | Jan 1, 2008 | Mar 1, 2013 | Aug 16, 2021 | 5 | United States |
safety will be assessed by monitoring lab results and adverse events, which will be assessed every 3 months for up to 2 years.
| Arm | Type | Description |
|---|---|---|
| veltuzumab | EXPERIMENTAL | veltuzumab is a humanized CD20 antibody administered subcutaneously in this study. |
| Name | Type | Description |
|---|---|---|
| veltuzumab | BIOLOGICAL | veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks. |
Inclusion Criteria: * Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL) * Either previously untreated or relapsed * Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria Exclusion Criteria:...